Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus Doxorubicin in Advanced Hepatocellular Carcinoma
NCT00108953Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2005
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Sorafenib + Doxorubicin with Placebo + Doxorubicin (2 arms). Primary endpoint: Time to Progression at 3 years. Started Apr 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00108953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00108953.